Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:CERS
Previous Symbol
CUSIP15708510
Phone925-288-6000
Debt
Debt-to-Equity Ratio0.29
Current Ratio5.03
Quick Ratio4.57
Price-To-Earnings
Trailing P/E Ratio-11.68
Forward P/E Ratio-15.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$51.33 million
Price / Sales17.05
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book19.24
Profitability
EPS (Most Recent Fiscal Year)($0.56)
Net Income$-60,580,000.00
Net Margins-76.37%
Return on Equity-82.60%
Return on Assets-42.37%
Miscellaneous
Employees215
Outstanding Shares133,810,000
Market Cap$887.19 million
OptionableN/A
Cerus (NASDAQ:CERS) Frequently Asked Questions
What is Cerus' stock symbol?
Cerus trades on the NASDAQ under the ticker symbol "CERS."
How were Cerus' earnings last quarter?
Cerus Co. (NASDAQ:CERS) released its earnings results on Thursday, August, 2nd. The biotechnology company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. The biotechnology company had revenue of $15.42 million for the quarter, compared to the consensus estimate of $13.58 million. Cerus had a negative return on equity of 82.60% and a negative net margin of 76.37%. The firm's revenue for the quarter was up 61.8% compared to the same quarter last year. During the same period last year, the business earned ($0.16) earnings per share. View Cerus' Earnings History.
When is Cerus' next earnings date?
What price target have analysts set for CERS?
4 equities research analysts have issued 12-month price objectives for Cerus' shares. Their forecasts range from $5.00 to $10.00. On average, they expect Cerus' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 22.3% from the stock's current price. View Analyst Price Targets for Cerus.
What is the consensus analysts' recommendation for Cerus?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.
What are Wall Street analysts saying about Cerus stock?
Here are some recent quotes from research analysts about Cerus stock:
- 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (10/5/2018)
- 2. Cantor Fitzgerald analysts commented, "We rate CERS Overweight and have a 12-month price target of $9. CERS commercializes INTERCEPT, the only FDA-approved system for pathogen- inactivated (PI) blood components. We believe 2018 will be a pivotal year for the company as it seeks to penetrate the platelet transfusion market in key geographical regions (US and internationally), which we expect to drive double-digit revenue growth longer term. CERS is seeking regulatory approval in Europe and the US to use its INTERCEPT system to treat red cells, a company-estimated $5B market." (10/3/2018)
Who are some of Cerus' key competitors?
Some companies that are related to Cerus include Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Nevro (NVRO), Atrion (ATRI), Luminex (LMNX), Cardiovascular Systems (CSII), K2M Group (KTWO), Tactile Systems Technology (TCMD), Cryolife (CRY) and AtriCure (ATRC).
Who are Cerus' key executives?
Cerus' management team includes the folowing people:
- Mr. William M. Greenman, Pres, CEO & Director (Age 51)
- Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 74)
- Mr. Kevin D. Green, VP of Fin. & CFO (Age 46)
- Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 47)
- Dr. Richard J. Benjamin, Chief Medical Officer (Age 58)
Who are Cerus' major shareholders?
Cerus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.25%), Essex Investment Management Co. LLC (0.36%), First Midwest Bank Trust Division (0.15%), First Manhattan Co. (0.05%) and First Quadrant L P CA (0.01%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Institutional Ownership Trends for Cerus.
Which institutional investors are selling Cerus stock?
CERS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and First Midwest Bank Trust Division. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.
Which institutional investors are buying Cerus stock?
CERS stock was bought by a variety of institutional investors in the last quarter, including First Manhattan Co., Essex Investment Management Co. LLC and First Quadrant L P CA. View Insider Buying and Selling for Cerus.
How do I buy shares of Cerus?
Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cerus' stock price today?
One share of CERS stock can currently be purchased for approximately $6.54.
How big of a company is Cerus?
Cerus has a market capitalization of $887.19 million and generates $51.33 million in revenue each year. The biotechnology company earns $-60,580,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cerus employs 215 workers across the globe.
What is Cerus' official website?
How can I contact Cerus?
Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]
MarketBeat Community Rating for Cerus (NASDAQ CERS)
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
